What is Amivantamab-vmjw Intravenous
Amivantamab-vmjw intravenous (trade name: AmiKet) is a monoclonal antibody which is used to treat cancer. It is a recombinant humanized IgG1 antibody that binds to human Vascular Endothelial Growth Factor (VEGF-A) with high affinity. VEGF-A is a protein that is involved in the growth and development of blood vessels. Amivantamab-vmjw intravenous is used to treat various types of cancer, including kidney cancer, colon cancer, and breast cancer. It is given as an infusion into a vein.
Benefits of Amivantamab-vmjw Intravenous
and Its Uses.
Amivantamab-vmjw intravenous is a monoclonal antibody that is used to treat cancer. It binds to a protein called vascular endothelial growth factor (VEGF), which is associated with the growth and progression of cancer. By blocking the action of VEGF, amivantamab-vmjw intravenous may help to slow or stop the growth of cancer cells.
Amivantamab-vmjw intravenous is used to treat a variety of cancers, including:
•Non-small cell lung cancer
Amivantamab-vmjw intravenous is given as an infusion (drip) into a vein. It is usually given once a week for a total of four doses.
Amivantamab-vmjw intravenous can cause side effects, including:
Side Effects and Dosage of Amivantamab-vmjw Intravenous
Amivantamab-vmjw is a monoclonal antibody that is used to treat cancer. It is given intravenously. The most common side effects are fever, chills, and headache. The most common dose is 10 mg per kilogram of body weight.